Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Abbott Laboratories

Share:
Related ABT
Fast Money Halftime Report Final Trade From March 11
3 Companies That Could Be Negatively Impacted By Johnson & Johnson Sale Of Cordis
Today's Market: REITs Grab Headlines, While IPOs And Secondaries Hit The Market (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Abbott Laboratories (NYSE: ABT), but lowered its price target from $87.00 to $39.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Abbott Laboratories closed on Tuesday at $33.36.

Latest Ratings for ABT

DateFirmActionFromTo
Mar 2015JefferiesMaintainsHold
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...